

March 06, 2020 2 min read

Patients with COVID-19 may experience GI symptoms, possible fecal-or

Results from two studies published in *Gastroenterology* discussed manifested gastrointestinal symptoms and fecal-oral transmission in patients with COVID-19, the disease caused by the novel coronavirus.

“Amounting evidence from former studies of SARS indicated that the gastrointestinal tract (in coronaviruses) was verified by the viral detection in biopsy specimens and stool, even though which may partially provide explanations for the gastrointestinal symptoms, potential recurrence of SARS from persistently shedding human as well,” **Jinyang Gu, MD**, of the department of translational medicine at the Shanghai Jiaotong University School of Medicine, and colleagues wrote in one of the studies.

Digestive symptoms of COVID-19

Two laboratories from China recently reported that they “successfully” isolated live 2019-nCoV from stool samples of COVID-19 patients, according to Gu and colleagues.

Before respiratory symptoms, many patients with COVID-19 had diarrhea, nausea, vomiting and abdominal pain, according to Gu and colleagues.

Key takeaways from studies:

There were 17 patients who remained positive in stool even after they demonstrated negative in respiratory samples.

Before respiratory symptoms, many patients with COVID-19 had diarrhea, nausea, vomiting and abdominal discomfort.

33 patients (20 males and 14 females) tested positive for SARS-CoV-2 RNA in stool.

Studies discussed manifested gastrointestinal symptoms and possible fecal-oral transmission in patients with COVID-19, the disease caused by the novel coronavirus.

“Surprisingly, recent single-cell RNA sequencing data from two independent cohorts revealed ACE2 expression in cholangiocytes (59.7% of cells) instead of hepatocytes (2.6% of cells) suggesting that SARS-CoV-2 infection might lead to direct damage of intrahepatic bile ducts,” the researchers wrote. “Altogether, these findings suggest that healthcare providers should be alert on the initial digestive symptoms of COVID-19 for early detection, early diagnosis, early treatment and early intervention.”

Signs for SARS-CoV-2

In accordance with Chinese CDC guidelines, Fei Xiao, MD, PhD, of the department of infectious diseases at the First Affiliated Hospital, Sun Yat-sen University, Guangdong, China, and colleagues obtained clinical specimens, which included serum, nasopharyngeal and oropharyngeal swabs, urine, stool and tissues, from 73 patients hospitalized with SARS-CoV-2 between Feb. 1 and 14. Then, using China CDC-standardized quantitative polymerase chain reaction, the researchers tested specimens for signs of SARS-CoV-2 RNA.

“Our immunofluorescent data showed that ACE2 protein, which has been proved to be a cell receptor for SARS-CoV-2, was abundantly expressed in the glandular cells of gastric, duodenal and rectal epithelia, supporting the hypothesis that ACE2 is the receptor into the host cells,” Xiao and colleagues wrote in the other study.

Endoscopy was used to obtain esophageal, gastric, duodenal and rectal tissues from one patient. After endoscopy, the researchers performed histological staining as well as viral receptor ACE2 and viral nucleocapsid protein staining. Immunofluorescence confocal microscopy (LSM880, Carl Zeiss MicroImaging) was used to obtain images of fluorescence.

Xiao and colleagues found that, of the 73 hospitalized patients with SARS-CoV-2, 39 patients (53%) tested positive for SARS-CoV-2 RNA in stool. Patients who tested positive for SARS-CoV-2 RNA ranged in age from 10 months to 78 years. Investigators noted the duration time of positive stool was between 17 and 100 days. Of the 39 patients who remained positive in stool even after they demonstrated negative in respiratory samples, 17 patients had positive stool samples for up to 100 days.

In the patient in which gastrointestinal endoscopy was performed, the mucous epithelium of esophagus, stomach, duodenum and rectum demonstrated no significant damage with histological staining. Xiao and colleagues found an infiltrate of occasional lymphocytes in esophageal squamous epithelium and in lamina propria of the stomach and rectum, numerous infiltrating plasma cells and lymphocytes with interstitial edema were observed in the lamina propria of the rectum.

According to the researchers, the viral host receptor ACE2 stained positive mostly in the cytoplasm of esophageal and rectal epithelial cells.

"Staining of viral nucleocapsid protein (NP) was visualized in the cytoplasm of gastric, duodenal epithelial cell, but not in esophageal epithelium," the researchers wrote. "The positive staining was also observed in gastrointestinal epithelium from other patients, who tested positive for S – by Monica Jaramillo

Disclosures: The authors report no relevant financial disclosures.

Published by:



Sources/Disclosures

Source: Gu J, et al. *Gastroenterology*. 2020;doi:10.1053/j.gastro.2020.02.054.
Xiao F, et al. *Gastroenterology*. 2020;doi:10.1053/j.gastro.2020.02.055.

Read more from COVID-19 Resource Center

November 06, 2024 | 2 min read |



Rural patients with AIRDs have 24% higher post-COVID mortality risk vs urban population

October 31, 2024 | 2 min read |



COVID-19 vaccination rates plummet among nursing home personnel

October 24, 2024 | 1 min read |



Study: Home dialysis access decreased during pandemic for patients with disabilities, ESKD



Read more about

[digestive tract](#)

[covid-19](#)

[coronavirus](#)

April 17, 2024 2 min read

Algorithm scans outpatient letters, identifies those who must 'shield' against COVID-19

Key takeaways:

- An algorithm analyzed outpatient letters to quickly determine who needed to 'shield' against guidelines.
- The algorithm could be applied to future public health initiatives.



Perspective from [Daniel J. Wallace, MD, FACP, MACR](#)

An automated algorithm designed to identify rheumatology patients who need to "shield" against COVID-19 has been developed by researchers at the University of Michigan.

[Continue reading](#)

Trending

Pulmonary Arterial Hypertension: Advances in Diagnosis and Treatment

Healio

Neurotrophic Keratitis: Improving Detection and Restoring Sensation

Healio

Injectable Solutions That Meet Treatment Goals in nAMD and DME Management

Healio

CME for Surgical Interventions for Retinal Vascular Diseases

Healio